Traws Pharma, Inc. reported positive topline Phase 1 results for ratutrelvir, its investigational oral Main protease (Mpro) inhibitor for COVID-19, on September 30, 2024. The study showed that ratutrelvir was well-tolerated over a 10-day administration period in healthy volunteers, with no treatment-related adverse events.
The Phase 1 data demonstrated that ratutrelvir achieved consistent plasma drug levels within the predicted therapeutic window, maintaining concentrations considerably above the EC90 against a comprehensive panel of SARS-CoV-2 viruses. A key differentiator is its ability to be administered without ritonavir co-administration, which is expected to reduce drug-drug interactions and expand patient eligibility.
Based on these positive results, Traws Pharma has selected the dose for its upcoming Phase 2a study, which is expected to commence in the first half of 2025. The company believes ratutrelvir has the potential to be a potent, best-in-class, once-a-day, 10-day antiviral therapy for COVID-19, potentially reducing the burden of treatment for patients with underlying medical conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.